1139 related articles for article (PubMed ID: 24053153)
21. Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study.
Inoue K; Anai S; Fujimoto K; Hirao Y; Furuse H; Kai F; Ozono S; Hara T; Matsuyama H; Oyama M; Ueno M; Fukuhara H; Narukawa M; Shuin T
Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):193-200. PubMed ID: 25843912
[TBL] [Abstract][Full Text] [Related]
22. Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.
Kobayashi K; Matsuyama H; Oka S; Nakamura K; Misumi T; Hiroyoshi T; Ito H; Isoyama N; Hirata H; Matsumoto H; Shiraishi K
Photodiagnosis Photodyn Ther; 2023 Mar; 41():103294. PubMed ID: 36681259
[TBL] [Abstract][Full Text] [Related]
23. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
Rolevich AI; Zhegalik AG; Mokhort AA; Minich AA; Vasilevich VY; Polyakov SL; Krasny SA; Sukonko OG
World J Urol; 2017 May; 35(5):745-752. PubMed ID: 27604374
[TBL] [Abstract][Full Text] [Related]
24. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
25. Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).
Bader MJ; Stepp H; Beyer W; Pongratz T; Sroka R; Kriegmair M; Zaak D; Welschof M; Tilki D; Stief CG; Waidelich R
Urol Oncol; 2013 Oct; 31(7):1178-83. PubMed ID: 22440147
[TBL] [Abstract][Full Text] [Related]
26. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
[TBL] [Abstract][Full Text] [Related]
27. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
[TBL] [Abstract][Full Text] [Related]
28. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
Ray ER; Chatterton K; Khan MS; Chandra A; Thomas K; Dasgupta P; O'Brien TS
BJU Int; 2010 Mar; 105(6):789-94. PubMed ID: 19832725
[TBL] [Abstract][Full Text] [Related]
29. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.
Naito S; Algaba F; Babjuk M; Bryan RT; Sun YH; Valiquette L; de la Rosette J;
Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749
[TBL] [Abstract][Full Text] [Related]
30. Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study).
Miyake M; Nishimura N; Inoue T; Suzuki S; Fujii T; Owari T; Hori S; Nakai Y; Toritsuka M; Nakagawa H; Tsukamoto S; Anai S; Torimoto K; Yoneda T; Tanaka N; Fujimoto K
Trials; 2021 Feb; 22(1):136. PubMed ID: 33579327
[TBL] [Abstract][Full Text] [Related]
31. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
33. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging.
Lee JY; Cho KS; Kang DH; Jung HD; Kwon JK; Oh CK; Ham WS; Choi YD
BMC Cancer; 2015 Aug; 15():566. PubMed ID: 26232037
[TBL] [Abstract][Full Text] [Related]
34. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?
Loidl W; Schmidbauer J; Susani M; Marberger M
Eur Urol; 2005 Mar; 47(3):323-6. PubMed ID: 15716195
[TBL] [Abstract][Full Text] [Related]
35. The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.
Renninger M; Fahmy O; Schubert T; Schmid MA; Hassan F; Stenzl A; Gakis G
World J Urol; 2020 Feb; 38(2):397-406. PubMed ID: 31030231
[TBL] [Abstract][Full Text] [Related]
36. Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis.
Lykke MR; Nielsen TK; Ebbensgaard NA; Zieger K
Scand J Urol; 2015 Jun; 49(3):230-6. PubMed ID: 25731785
[TBL] [Abstract][Full Text] [Related]
37. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
O'Brien T; Ray E; Singh R; Coker B; Beard R;
Eur Urol; 2011 Oct; 60(4):703-10. PubMed ID: 21684068
[TBL] [Abstract][Full Text] [Related]
38. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
[TBL] [Abstract][Full Text] [Related]
39. [Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis].
Kausch I; Sommerauer M; Montorsi F; Stenzl A; Jacqmin D; Jichlinski P; Jocham D; Ziegler A; Vonthein R
Aktuelle Urol; 2010 May; 41(3):171-7. PubMed ID: 20486035
[TBL] [Abstract][Full Text] [Related]
40. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
